LGC AXIO Proficiency Testing | 2026 Catalogue

AXIO | Proficiency Testing schemes 2026

Quantity of Matrix

Rounds per Year

Sample Code Matrix

Analytes

PT-QZ-01+02 Blood

2 x 10ml

Sample 1: Participants will be asked to identify up to 4 drugs relevant to forensic toxicology; Sample 2: Quantification of a known drug (full identity or generic classification)

4

PT-QZ-03

Blood

2 x 10ml

Sample 3A: Morphine, Methadone, Amphetamine Diazepam. Sample 3B: Citalopram, Codeine, Amitriptyline, Tramadol

2

PT-QZ-04

Blood

10ml

Quantification of alcohol and fluoride in a blood sample 2 Interpretation of a case study (with analytical data, and a scenario or witness statement) to determine the potential blood alcohol level at a given time 2 Participants are asked to quantify/identify a range of new psychoactive substances; (NPS). Two substances are named and are for quantification and a further two substances are not named and are to be identified by screening (quantification results may also be included) 2

PT-QZ-05

Paper exercise

-

PT-QZ-06

Blood

10ml

PT-QZ-07

Blood

10ml

Participants are asked to screen for synthetic cannabinoids and identify one of the most common synthetic cannabinoids Participants are asked to identify up to 4 drugs or metabolites relevant to forensic toxicology

2

PT-QZ-08

Urine

10ml

2

PT-QZ-09

Urine

10ml

A urine sample specifically for New Psychoactive Substance screening and may include synthetic cannabinoids. Up to two substances may be present. No interpretation is required 2 Sample 10A: Oxycodone, Pregabalin, MDMA and Mirtazapine Sample 10B: Loratidine, Gabapentin, Quetiapine and Valproate 2

PT-QZ-10

Blood

2 x 10ml

Download Application Form Download Scheme Description

lgcstandards.com/AXIO 121

Made with FlippingBook - professional solution for displaying marketing and sales documents online